EyePoint, Inc. EYPT 深 滬
等待開盤 03-26 09:30:00 美东时间
13.05
+0.460
+3.65%
華盛通- 最 高13.33
- 今 開12.70
- 成交量 68.74万股
- 最 低 12.70
- 昨 收 12.59
- 總市值 10.89亿
- 52周最高 19.11
- 市盈率 靜 --
- 換手率 0.82%
- 52周最低 3.91
- 委 比 33.51%
- 總股本 8343.20万
- 歷史最高 39.40
- 量 比 0.76
- 振 幅 5.00%
- 歷史最低 2.19
- 每 手 1
- 風險率 3.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多新浪财经ESG：EyePoint Pharmaceuticals Inc. MSCI（明晟）ESG评级调降至BBB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:19
EyePoint sues Ocular over claims related to lead asset
EyePoint (EYPT) has filed a lawsuit against Ocular Therapeutix (OCUL) in a Massachusetts federal court, alleging that its rival eye drug developer made false claims regarding its lead candidate, Durav...
03-21 22:23
EyePoint Sues Ocular Therapeutix Over Alleged Defamation
EyePoint Pharmaceuticals ( ($EYPT) ) has provided an announcement. On March 20,...
03-21 05:04
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
RBC Capital Markets has compiled a list of 13 biotechs that are most likely to receive takeover interest, including Revolution Medicines (RVMD), Ascendis Pharma (ASND), and Arrowhead Pharma (ARWR), am...
03-20 02:37
EyePoint grants 20,000 inducement stock options at USD 13.2 per share
EyePoint grants 20,000 inducement stock options at USD 13.2 per share EyePoint reported granting non-statutory stock options covering 20,000 shares to six new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The options were granted on March 13, 2026, with an exercise price
03-16 19:02
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. granted non-statutory stock options to six new employees outside its 2023 Long-Term Incentive Plan, totaling 20,000 shares. The options, granted on March 13, 2026, have an exercise price of $13.20 per share, based on the closing price that day, and vest over four years. The Company focuses on developing therapies for serious retinal diseases, with its lead candidate, DURAVYU™, in Phase 3 trials for wet AMD and DME. Topline data for...
03-16 11:00
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
Marriott Vacations To Rally Around 52%? Here Are 10 Top Analyst Forecasts For Thursday
Summary:Top Wall Street analysts changed outlook on top names. Analyst ratings page shows all changes. VEEV, GENI, DOW, BLLN, OKTA, VAC, WLK, EYPT had price target changes.
03-05 20:06
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
